Press Releases

Apr 21, 2026

Priya Menon

Press Releases

Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

Foghorn Therapeutics presented new preclinical data demonstrating the efficacy and safety of its innovative drug candidates targeting chromatin regulatory proteins involved in cancer. The lead compound, selective SMARCA2 inhibitor FHD-909, in combination with an anti-PD-1 antibody, showed complete and durable tumor regression and immune memory in m…

FHTX

Apr 21, 2026

Priya Menon

Press Releases

Monarch Casino & Resort Reports Record First Quarter 2026 Financial Results

Monarch Casino & Resort, Inc. reported record financial results for Q1 2026, with net revenue increasing 8.9% to $136.6 million and net income rising 38.9% to $27.6 million compared to the prior year. Adjusted EBITDA grew 19% and margins improved significantly. The company increased market share at both its Atlantis and Monarch Black Hawk propertie…

MCRI

Apr 21, 2026

Ajmal Hussain

Press Releases

Beta Bionics Announces First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance

Beta Bionics announced a 57% year-over-year increase in net sales for Q1 2026, driven by growth in both Durable Medical Equipment and Pharmacy Benefit Plan channels. The company improved its gross margin significantly and reduced its net loss compared to Q1 2025. Beta Bionics also raised its full-year 2026 revenue and gross margin guidance, reflect…

BBNX

Apr 21, 2026

Sofia Navarro

Press Releases

Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting

Olema Oncology announced it will present initial Phase 1 clinical data for its investigational drug OP-3136, a novel selective KAT6A/B inhibitor, at the 2026 ASCO Annual Meeting. The company will also provide updates on its ongoing Phase 3 OPERA-02 trial involving palazestrant plus ribociclib for advanced breast cancer. OP-3136 shows potent anti-pr…

OLMA

Apr 21, 2026

Leila Farooq

Press Releases

Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States

Wave Life Sciences, a biotechnology company developing RNA-based medicines, has filed for shareholder and Singapore High Court approvals to redomicile its parent company from Singapore to the United States. The move aims to position the company advantageously for future growth and regulatory alignment, subject to customary approvals and closing con…

WVE

Apr 21, 2026

Sofia Navarro

Press Releases

TrustCo Reports First Quarter 2026 Net Income of $16.3 Million; Notes Loan Portfolio Repricing

TrustCo Bank Corp NY reported a net income of $16.3 million for the first quarter of 2026, a 14.1% increase from the prior year. The bank's net interest income grew 10.7% to $44.7 million due to successful loan portfolio repricing and disciplined deposit pricing strategies, which led to a 20 basis point expansion in net interest margin to 2.84%. Lo…

TRST

Apr 21, 2026

Avery Klein

Press Releases

Cytokinetics to Announce First Quarter Results on May 5, 2026

Cytokinetics, a biopharmaceutical company specializing in cardiac muscle biology, announced its plan to release first quarter 2026 financial results on May 5, 2026, followed by a management conference call to discuss its financial performance and business updates. The company is advancing its pipeline of cardiac therapies, including the approved dr…

CYTK

Apr 21, 2026

Leila Farooq

Press Releases

Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease

Belite Bio has initiated the rolling submission of a New Drug Application (NDA) to the FDA for tinlarebant, an oral therapy aimed at treating Stargardt disease type 1 (STGD1). The drug has received Breakthrough Therapy Designation and is backed by positive Phase 3 clinical data. The company plans to complete submission by Q2 2026 and is preparing f…

BLTE

Apr 21, 2026

Maya Rios

Press Releases

F&M Bank Announces Appointment of Shalini Singhal to Chief Information and Technology Officer

Farmers & Merchants Bancorp, Inc. (Nasdaq: FMAO), parent company of F&M Bank, announced the appointment of Shalini Singhal as Chief Information and Technology Officer. Singhal, previously the Chief Information Officer, will lead technology strategy focusing on innovation, digital transformation, and cybersecurity to support business growth and oper…

FMAO

Apr 21, 2026

Nina Shah

Press Releases

Fortinet Wins 2026 Google Cloud Partner of the Year Award for Workload Security

Fortinet Inc. has been honored as the 2026 Google Cloud Partner of the Year for Workload Security, recognizing its FortiCNAPP platform's innovative integration and protection of cloud workloads across hybrid and multi-cloud environments. The award emphasizes Fortinet's leadership in cloud security and its collaborative partnership with Google Cloud…

FTNT

Apr 21, 2026

Jordan Park

Press Releases

Quadrant Reaches New Heights With F1 Drivers Collaboration

Sports Entertainment Gaming Global Corporation's subsidiary Quadrant has released a high-engagement YouTube video featuring Formula 1 drivers Carlos Sainz Jr. and Lando Norris, celebrating the 100th anniversary of karting. The campaign generated over four million views and significant social media impressions, reinforcing Quadrant's content strateg…

SEGG

Apr 21, 2026

Hana Yamamoto

Press Releases

Independent Bank Corporation Announces Quarterly Cash Dividend On Common Stock

Independent Bank Corporation announced a quarterly cash dividend of $0.28 per share payable on May 14, 2026, to shareholders of record as of May 4, 2026. The Michigan-based community bank holds approximately $5.5 billion in assets and provides a full range of financial services throughout Michigan's Lower Peninsula.

IBCP

Apr 21, 2026

Jordan Park

Press Releases

S&P upgrades SiriusPoint’s Insurance Subsidiaries to ‘A’ based on consistent robust earnings and strength of capital position

SiriusPoint Ltd has received an upgrade from S&P Global Ratings on its core insurance operating subsidiaries to 'A' from 'A-', marking the company's third upgrade this year. The holding company rating was also raised to 'BBB+' from 'BBB' with a stable outlook. The upgrades are attributed to SiriusPoint's consistent underwriting performance, de-risk…

SPNT

Apr 21, 2026

Avery Klein

Press Releases

Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation

Royalty Pharma plc has announced the establishment of the Royalty Pharma Translational Prize, an annual $1 million award recognizing scientists who have successfully translated fundamental scientific discoveries into impactful new medicines. The prize aims to encourage translational research and will be awarded by an independent committee chaired b…

RPRX

Apr 21, 2026

Maya Rios

Press Releases

Table for Mom: OpenTable Launches Mother’s Day Dining Trends and Canada’s Top 100 Brunch and Lunch Restaurants for 2026

OpenTable, part of Booking Holdings, Inc., announced its annual Top 100 Brunch and Lunch Restaurants in Canada for 2026 and shared consumer trends for Mother’s Day dining, revealing that 65% of Canadians consider dining out an important part of their celebration. The data highlights evolving celebration styles including solo dining, larger family g…

BKNG

Apr 21, 2026

Ajmal Hussain

Press Releases

United Fire Group, Inc. announces its first quarter 2026 earnings call

United Fire Group, Inc. announced it will release its first quarter 2026 earnings results after market close on May 5, 2026, followed by an earnings call on May 6. The company invites analysts, investors, and stakeholders to participate via teleconference or webcast. The event will be archived for replay and a transcript will be available. United F…

UFCS

Apr 21, 2026

Avery Klein

Press Releases

Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting

Revolution Medicines announced that detailed results from its pivotal Phase 3 RASolute 302 clinical trial of daraxonrasib, an oral RAS(ON) multi-selective inhibitor, in previously treated metastatic pancreatic ductal adenocarcinoma patients, will be presented at the 2026 ASCO Annual Meeting. The topline data showed statistically significant and cli…

RVMD

Apr 21, 2026

Marcus Reed

Press Releases

Northeast Bank Announces Dates for Fiscal 2026 Third Quarter Earnings Results and Conference Call

Northeast Bank announced it will release its fiscal 2026 third quarter earnings on April 27, 2026, followed by a conference call on April 28, 2026. The call will be hosted by senior executives and available via live webcast and phone. Northeast Bank operates as a national lender and community bank, focusing on commercial real estate loans and small…

NBN

Apr 21, 2026

Ajmal Hussain

Press Releases

Alexander’s Announces First Quarter Earnings Release Date and Vornado Realty Trust Quarterly Conference Call

Alexander's, Inc., a New York City-based real estate investment trust, will release its Q1 2026 earnings on May 4, 2026, before market open. Vornado Realty Trust, the manager of Alexander's operations, will host a conference call on May 5, 2026, discussing quarterly results including those related to Alexander's. The company highlighted typical for…

ALX

Apr 21, 2026

Maya Rios

Press Releases

Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting

Black Diamond Therapeutics announced multiple presentations at the 2026 ASCO Annual Meeting showcasing Phase 2 data of their brain-penetrant EGFR inhibitor, Silevertinib, in non-small cell lung cancer (NSCLC) and glioblastoma (GBM) patients. Early data indicate promising efficacy and safety profiles, including a 60% objective response rate in front…

BDTX

Apr 21, 2026

Maya Rios

Press Releases

Vornado Announces First Quarter Earnings Release Date and Conference Call Information

Vornado Realty Trust announced it will release its first quarter 2026 earnings report on May 4, 2026, after the NYSE closes. The company will host a conference call and webcast on May 5, 2026 to discuss the quarterly results. Forward-looking statements highlight risks related to interest rate fluctuations, inflation, and their potential impact on t…

VNO

Apr 21, 2026

Maya Rios

Press Releases

Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial

Regeneron Pharmaceuticals reported positive Phase 3 NIMBLE trial results for cemdisiran, an investigational siRNA therapy targeting complement factor 5 (C5), demonstrating rapid, deep, and sustained disease control in adults with generalized myasthenia gravis (gMG). The trial met primary and key secondary endpoints at 24 weeks, showing significant …

REGN

Apr 21, 2026

Caleb Monroe

Press Releases

Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer

Zentalis Pharmaceuticals announced that an abstract highlighting results from Part 1 of their MUIR trial, testing azenosertib in combination with paclitaxel for platinum-resistant ovarian cancer, has been accepted for presentation at the ASCO 2026 Annual Meeting. Azenosertib, a first-in-class WEE1 inhibitor, is being developed as a biomarker-driven…

ZNTL

Apr 21, 2026

Sofia Navarro

Press Releases

Skyworks Sets Date for Second Quarter Fiscal 2026 Earnings Release and Conference Call

Skyworks Solutions, Inc. will release its second quarter fiscal 2026 earnings on May 5, 2026, followed by a conference call to discuss results and business outlook. The company provides analog and mixed-signal semiconductors across various sectors including wireless networking, aerospace, automotive, and consumer electronics.

SWKS

Apr 21, 2026

Jordan Park

Press Releases

Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting

Immatics N.V. announced that four abstracts from its clinical cell therapy and bispecific T-cell engager pipeline have been selected for oral presentations at the 2026 ASCO Annual Meeting. Data highlights include Phase 1b results of anzu-cel in melanoma, updated Phase 1a/b data for second-generation IMA203CD8 in gynecologic cancers, findings on PRA…

IMTX